Riskpilot← Back to searchSign inGet full accessMedivalv AB
ABActiveOrg 5569443012Physiotherapy activities · NACE 8695Est. 20131 employees
Revenue 2024
SEK 20K
-89% vs 2023
EBITDA margin
-70.0%
+76% vs 2023
Equity ratio
-533.3%
Financial strength
Net profit 2024
SEK -19K
+67% vs 2023
| Revenue | SEK 20K | -89% |
| EBITDA | SEK -14K | +76% |
| Net profit | SEK -19K | +67% |
| Total assets | SEK 3K | -97% |
| Equity | SEK -16K | -633% |
| Employees | 1 | — |
Legal name
Medivalv AB
Org number
5569443012
Legal form
Aktiebolag
NACE code
8695 · Physiotherapy activities
Founded
3 oktober 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva hälsovård, främst medicinsk fotvård, borttagning av hårväxt, hudvård, skönhetsbehandling, nagelvård, massage, laserbehandling, borttagning av tatueringar samt närliggande hälsovård. Företaget skall även bedriva konsultverksamhet i hälsovård och försäljning. Även undervisning och läxhjälp.
Address
Email
kontakt@medivalv.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 174 | 234 | 213 | 182 | 20 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 25 | −25 | −13 | −58 | −14 |
| Depreciation & amort. | −6 | −6 | −0 | −0 | −0 |
| EBIT | 19 | −31 | −13 | −58 | −14 |
| Net financials | — | — | — | — | −4 |
| Profit before tax | 19 | −31 | −13 | −57 | −19 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 19 | −31 | −13 | −57 | −19 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 130 | 95 | 92 | 119 | 3 |
| Equity | 104 | 74 | 60 | 3 | −16 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 26 | 22 | 31 | 116 | 19 |
| Total debt | 26 | 22 | 31 | 116 | 19 |
EBITDA margin
-70.0%
This company
15.8%
Market median
-543% vs market
20202024
Equity ratio
-533.3%
This company
38.2%
Market median
-1496% vs market
20202024
Return on equity
-1900000.0%
This company
18.4%
Market median
-10326187% vs market
20202024
Net profit margin
-95.0%
This company
8.1%
Market median
-1273% vs market
20202024
Asset turnover
6.67×
This company
1.12×
Market median
+496% vs market
20202024
Debt / equity
1.19×
This company
0.62×
Market median
-92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JJ Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medivalv AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Julia Jagna Lilja | Chief Executive Officer | 0 companies |
| Tonny Kenneth Lilja | Deputy Board Member | 0 companies |
| Saga Pauline Daria Kardelo | Deputy Board Member | 0 companies |